Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/34573
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHotterbeekx, An-
dc.contributor.authorDusabimana, Alfred-
dc.contributor.authorMandro, Michel-
dc.contributor.authorAbhafule, Germain M-
dc.contributor.authorDeogratias, Wonya’Rossy-
dc.contributor.authorSiewe Fodjo, Joseph N.-
dc.contributor.authorABRAMS, Steven-
dc.contributor.authorColebunders, Robert-
dc.date.accessioned2021-07-26T15:11:40Z-
dc.date.available2021-07-26T15:11:40Z-
dc.date.issued2020-
dc.date.submitted2021-07-09T14:22:20Z-
dc.identifier.citationPathogens, 9 (3) (Art N° 191)-
dc.identifier.urihttp://hdl.handle.net/1942/34573-
dc.description.abstractWe investigated urinary N-acetyltyramine-O,beta-glucuronide (NATOG) levels as a biomarker for active Onchocerca volvulus infection in an onchocerciasis-endemic area in the Democratic Republic of Congo with a high epilepsy prevalence. Urinary NATOG was measured in non-epileptic men with and without O. volvulus infection, and in O. volvulus-infected persons with epilepsy (PWE). Urinary NATOG concentration was positively associated with microfilarial density (p < 0.001). The median urinary NATOG concentration was higher in PWE (3.67 mu M) compared to men without epilepsy (1.74 mu M), p = 0.017; and was higher in persons with severe (7.62 mu M) compared to mild epilepsy (2.16 mu M); p = 0.008. Non-epileptic participants with and without O. volvulus infection had similar NATOG levels (2.23 mu M and 0.71 mu M, p = 0.426). In a receiver operating characteristic curve analysis to investigate the diagnostic value of urinary NATOG, the area under the curve was 0.721 (95% CI: 0.633-0.797). Using the previously proposed cut-off value of 13 mu M to distinguish between an active O. volvulus infection and an uninfected state, the sensitivity was 15.9% and the specificity 95.9%. In conclusion, an O. volvulus infection is associated with an increased urinary NATOG concentration, which correlates with the individual parasitic load. However, the NATOG concentration has a low discriminating power to differentiate between infected and uninfected individuals.-
dc.description.sponsorshipFunding: The study was funded by a grant from the European Research Council (ERC 671055). The study sponsors, ERC and Janssen Global Public Health, had no role in the design, execution, interpretation, or writing of the study. Acknowledgments: We thank Malteser International for organizing the treatment for PWE in the Logo health zone, the local health personnel and community workers taking care of the PWE, and all the participants in the study. We also thank Janssen Global Public Health, in particular Lieven Stuyver and Ole Lagatie and the staff of the Bioanalysis team, for the analysis of the urinary NATOG concentrations. This analysis was an in-kind contribution form Janssen Global Public Health to the OAE research.-
dc.language.isoen-
dc.publisherMDPI-
dc.rights2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).-
dc.subject.otherOnchocerca volvulus-
dc.subject.otherN-acetyltyramine-O,β-glucuronide (NATOG), epilepsy-
dc.subject.otherAfrica-
dc.subject.otherbiomarker-
dc.subject.otherurine-
dc.titleUrinary N-acetyltyramine-O,β-glucuronide in Persons with Onchocerciasis-Associated Epilepsy-
dc.typeJournal Contribution-
dc.identifier.issue3-
dc.identifier.volume9-
local.bibliographicCitation.jcatA1-
local.publisher.placeST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr191-
dc.identifier.doi10.3390/pathogens9030191-
dc.identifier.pmid32151038-
dc.identifier.isiWOS:000524306100018-
dc.contributor.orcidFodjo, Joseph Nelson Siewe/0000-0003-3544-1239; Hotterbeekx,-
dc.contributor.orcidAn/0000-0003-3356-4032; Colebunders, Robert/0000-0002-1919-1340-
dc.identifier.eissn2076-0817-
local.provider.typewosris-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorHotterbeekx, An-
item.contributorDusabimana, Alfred-
item.contributorMandro, Michel-
item.contributorAbhafule, Germain M-
item.contributorDeogratias, Wonya’Rossy-
item.contributorSiewe Fodjo, Joseph N.-
item.contributorABRAMS, Steven-
item.contributorColebunders, Robert-
item.fullcitationHotterbeekx, An; Dusabimana, Alfred; Mandro, Michel; Abhafule, Germain M; Deogratias, Wonya’Rossy; Siewe Fodjo, Joseph N.; ABRAMS, Steven & Colebunders, Robert (2020) Urinary N-acetyltyramine-O,β-glucuronide in Persons with Onchocerciasis-Associated Epilepsy. In: Pathogens, 9 (3) (Art N° 191).-
item.accessRightsOpen Access-
item.validationecoom 2021-
crisitem.journal.eissn2076-0817-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
pathogens-09-00191-v2.pdfPublished version668.32 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.